259231-45-3

Upstream product

• 2622-05-1 allylmagnesium bromide 
• 259231-44-2 ((1S,3R,4R,5R,6R)-5-Benzyloxy-3-trityloxymethyl-2,7-dioxa-bicyclo[4.1.0]hept-4-yloxy)-tert-butyl-dimethyl-silane 
• 259231-42-0 (2R,3S,4R)-4-Benzyloxy-2-trityloxymethyl-3,4-dihydro-2H-pyran-3-ol 
• 100-39-0 benzyl bromide 
• 122350-80-5 1,5-anhydro-2-deoxy-6-O-trityl-D-arabino-hex-1-enitol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 259231-43-1 (4-benzyloxy-2-trityloxymethyl-3,4-dihydro-2H-pyran-3-yloxy)-tert-butyl-dimethyl-silane 

Downstream Products

• 259231-47-5 ((2R,3R,4R,4aS,9aS)-4-Benzyloxy-2-trityloxymethyl-3,4,4a,6,9,9a-hexahydro-2H-1,5-dioxa-benzocyclohepten-3-yloxy)-tert-butyl-dimethyl-silane 
• 259231-54-4 (2S,3S,4R,5R,6R)-2-Allyl-3,5-bis-allyloxy-4-benzyloxy-6-trityloxymethyl-tetrahydro-pyran 
• 259231-49-7 (2R,3R,4R,4aS,9aS)-3-Allyloxy-4-benzyloxy-2-trityloxymethyl-3,4,4a,6,9,9a-hexahydro-2H-1,5-dioxa-benzocycloheptene 
• 259231-48-6 (2R,3R,4S,4aS,9aS)-4-Benzyloxy-2-trityloxymethyl-3,4,4a,6,9,9a-hexahydro-2H-1,5-dioxa-benzocyclohepten-3-ol 
• 259231-55-5 ((2R,3R,4R,5S,6S)-6-Allyl-3,5-bis-allyloxy-4-benzyloxy-tetrahydro-pyran-2-yl)-methanol 
• 259231-56-6 (2S,3S,4R,5R,6R)-2-Allyl-3,5-bis-allyloxy-4-benzyloxy-6-vinyl-tetrahydro-pyran 
• 259231-50-0 ((2R,3R,4R,4aS,9aS)-3-Allyloxy-4-benzyloxy-3,4,4a,6,9,9a-hexahydro-2H-1,5-dioxa-benzocyclohepten-2-yl)-methanol 
• 259231-51-1 (2R,3R,4R,4aS,9aS)-3-Allyloxy-4-benzyloxy-2-vinyl-3,4,4a,6,9,9a-hexahydro-2H-1,5-dioxa-benzocycloheptene 
• 511511-35-6 (2S,3S,4R,5R,6R)-2-Allyl-4-benzyloxy-5-(tert-butyl-dimethyl-silanyloxy)-6-hydroxymethyl-tetrahydro-pyran-3-ol 
• 259231-53-3 (2S,3S,4R,5R,6R)-2-Allyl-4-benzyloxy-6-trityloxymethyl-tetrahydro-pyran-3,5-diol 
• 259231-46-4 ((2R,3R,4R,5S,6S)-6-Allyl-5-allyloxy-4-benzyloxy-2-trityloxymethyl-tetrahydro-pyran-3-yloxy)-tert-butyl-dimethyl-silane 

Relevant academic research and scientific papers

Probing the heparin - Antithrombin III interaction using synthetic pentasaccharides bearing positively charged groups

Four heparin pentasaccharides bearing either one (i.e. 3b and 4b) or two (i.e. 3c and 4c) positively charged amino groups at the reducing end have been synthesized and evaluated for their antithrombin III mediated anti-Xa activity. The positively charged groups were introduced to interact specifically with the negatively charged amino acid residues Glu113 and Asp117 of antithrombin III, which are located in the heparin binding site in close proximity to the reducing end of the saccharide. It turned out that the target compounds 3b,c and 4b,c exhibited relatively low anti-Xa activities, indicating unfavorable interactions between the new pentasaccharides and antithrombin III rather than the anticipated enhancement of association. Wiley-VCH Verlag GmbH, 69451 Weinheim, Germany, 2002.

Synthesis of a trans-fused tricyclic ether using a novel differentially protected glucal

The construction of the trans-fused 7,6,6-ABC fragment (3) of ciguatoxin 3C, starting from the novel carbohydrate derivative 3-O-benzyl-4-O-tert- butyldimethylsilyl-6-O-trityl-D-glucal, is reported. The formation of the A- and C-rings can be effected by executing two individual ring-closing metathesis steps in a sequential or a one-pot procedure.